Sintilimab as adjuvant therapy for patients with resected HCC at high risk of recurrence
Sintilimab as adjuvant therapy for patients with resected HCC at high risk of recurrence
About this item
Full title
Sintilimab as adjuvant therapy for patients with resected HCC at high risk of recurrence
Author / Creator
Publisher
London: Nature Publishing Group UK
Journal title
Nature reviews. Gastroenterology & hepatology, 2024-03, Vol.21 (3), p.141-141
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Alternative Titles
Full title
Sintilimab as adjuvant therapy for patients with resected HCC at high risk of recurrence
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_2926079894
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2926079894
Other Identifiers
ISSN
1759-5045
E-ISSN
1759-5053
DOI
10.1038/s41575-024-00904-5
